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We designed and synthesized a new class of 13C-labeled NMR probe, 13C-IQ-Gd, to 
monitor one-electron reductions by cytochrome:P450 (CYP450) reductase under 
hypoxic conditions. 13C-IQ-Gd consisted of a Gd3+-diethylene triamine pentaacetic acid 
(DTPA) complex unit and an indolequinone (13C-IQ) unit bearing a 13C-labeled 
methoxy group. The 13C-NMR signal of 13C-IQ-Gd was suppressed because of the 
intramolecular paramagnetic effect of Gd3+, whereas enzymatic reduction mediated by 
CYP450 reducatase under hypoxic conditions yielded an intensed 13C-NMR signal due 
to enzymatic activation of the IQ unit followed by release of the DTPA-Gd unit from 
13C-IQ-Gd. This 13C-NMR spectral change allowed the monitoring of CYP450 
reducatase-mediated one-electron reduction. 
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Cytochrome:P450 (CYP450) reductase catalyzes one-electron reduction of various 
substrates with the aid of cofactors such as -NADPH. CYP450 reductase has been 
identified to play key functions in liver detoxification, biological synthesis of steroid 
hormones, metabolism of fatty acids and drug activation in malignant tumor cells.1,2 In 
particular, the enzyme operates effectively in tumor hypoxia that characterizes various 
types of solid tumor tissues.3 Under hypoxic conditions, CYP450 reductase activates 
certain drugs and molecular probes, which allows the expression of their inherent 
functions.4,5 In this context, one-electron reduction mediated by CYP450 reductase has 
attracted considerable attention for designing hypoxia-targeting drugs and probes. 
Recently, highly sensitive and sophisticated 13C NMR/MRI techniques such as 
multiple-resonance6 and hyperpolarized NMR have been developed.7 In this association, 
various types of 13C-labeled compounds have been thitherto reported for application to 
highly sensitive 13C-NMR analysis of complicated biological systems due to low level 
of natural 13C abundance.8 
The present study aims at developing a new class of 13C-NMR probe to monitor 
CYP450 reductase-mediated one-electron reduction. We designed and synthesized a 
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conjugate (13C-IQ-Gd) consisting of a Gd3+-diethylene triamine pentaacetic acid 
(DTPA) complex unit9 and a 13C-labeled indolequinone (13C-IQ) unit that undergoes 
one-electron reduction by CYP450 reductase (Figure 1). 13C-IQ-Gd alone showed no 
apparent signal in the 13C-NMR spectrum because of the intramolecular paramagnetic 
effect of Gd3+,10 whereas the 13C-IQ unit was activated upon treatment with 
one-electron reducing CYP450 reductase to be separated from the Gd-DTPA unit and 




The synthesis of 13C-IQ-Gd is outlined in Scheme 1. The hydroxyl group of 1 was 
methylated by means of 13C-labeled methyl iodide, and following nitration and 
reduction gave aminoindole (3). The resulting 3 was converted into indolequinone 
(13C-IQ-OH) via treatment with LiAlH4 and Fremy’s salt, and was then coupled with 
DTPA to give 13C-IQ-DTPA.12 Finally, 13C-IQ-DTPA was coordinated with Gd3+ to 
give 13C-IQ-Gd.13 The NMR probe 13C-IQ-Gd thus obtained was water soluble up to 4 
 5
mM. We confirmed that metal coordination resulted in a broadening and weakening in 
13C-NMR signal at 57 ppm of the original 13C-IQ-DTPA (Figure 2B) because of the 




Upon incubation of 13C-IQ-Gd with CYP450 reductase and its cofactor -NADPH in 
hypoxic aqueous solution14 the reaction was monitored by 13C-NMR. As shown in 
Figure 2C, a new signal appeared at 63 ppm after the enzymatic treatment for 1 h. This 
response is consistent with the present molecular design. 13C-IQ-Gd was activated by 
enzymatic reduction to release the DTPA-Gd unit, resulting in the appearance of a 13C 
NMR signal along with a decreased extent of intramolecular paramagnetic effect due to 
separation of the 13C-labeled IQ unit from the DTPA-Gd unit. In contrast, aerobic 
enzymatic reduction of 13C-IQ-Gd by CYP450 reductase yielded no apparent signal 
(Figure 2D). These results indicate that the enzymatic reduction of 13C-IQ-Gd occurred 





For further characterization of this enzymatic reduction, we performed a similar 
enzymatic reaction of 13C-IQ-OH without bearing a DTPA-Gd unit that showed a 
distinct signal at 57 ppm in 13C-NMR (Figure 3A) in contrast to 13C-IQ-Gd. After 
treatment with CYP450 reductase in the presence of -NADPH for 1 h in hypoxic 
phosphate buffer, we observed appearance of a new 13C-NMR signal at 63 ppm (Figure 
3B),15 which is identical with the signal resulted from 13C-IQ-Gd upon similar 
enzymatic treatment. These results are a strong indication that the 13C-IQ unit was 
activated by CYP450 reductase to be released from 13C-IQ-Gd or 13C-IQ-OH during 
the enzymatic reaction. Recent studies on the activation mechanism of IQ derivatives 
under reduction conditions demonstrated that IQ was converted to an electrophilic 
intermediate 4, which was trapped by ambient nucleophiles (Figure 4).16 In this context, 
one of the possible reaction products that yielded a characteristic 13C-NMR signal at 63 
ppm is a 13C-IQ-protein adduct. We therefore attempted to identify the reaction 
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products. However, the product characterization was unsuccessful, because purification 





An attempt was also made to feature the selective activation of 13C-IQ-Gd by CYP450 
reductase.17 We compared enzymatic activity toward 13C-IQ-Gd of CYP450 reductase 
with five other oxidases and reductases such as glucose dehydrogenase, alcohol 
dehydrogenase, peroxidase, nitrate reductase, and flavin reductase. In contrast to 
CYP450 reductase (see Figure 2C), incubation of 13C-IQ-Gd with the other enzymes 
failed to give signal in 13C NMR (Figure S1). Thus, it is most likely that 13C-IQ-Gd 
undergoes one-electron reduction exclusively by CYP450 reductase. 
In summary, we designed and synthesized a new class of 13C-labeled NMR probe for 
monitoring of enzymatic one-electron reduction by CYP450 reductase. The reduction of 
13C-IQ-Gd, which consisted of a 13C-labeled IQ unit and a DTPA-Gd unit, was 
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monitored by 13C-NMR. Hypoxia-selective activation of 13C-IQ-Gd induced 
appearance of a 13C-NMR signal of the 13C-methoxy group in the IQ unit, which was 
attributable to a decreased extent of the intramolecular paramagnetic effect of Gd3+. In 
view of these properties, 13C-IQ-Gd is a promising candidate for an NMR probe for the 
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Scheme 1. Reagents: (a) NaH, 13CH3I, 64%; (b) HNO3, AcOH, 78%; (c) Sn, HCl, EtOH, 
76%; (d) LiAlH4, THF; (e) Fremy’s salt, Me2CO, NaH2PO4, water, 77% in 2 steps; (f) 

















Figure 1. (A) Molecular design of 13C-IQ-Gd as a probe for one-electron reduction by 




















Figure 2. 13C-NMR spectra of (A) 13C-IQ-DTPA alone and (B, C, D) 13C-IQ-Gd upon 
treatment with CYP450 reductase (10 g/mL) in the presence of -NADPH (2 mM) at 
37 ˚C in phosphate buffer (pH 7.4): (B) before treatment with reductase; (C) treated 















Figure 3. 13C-NMR spectra of 13C-IQ-OH (2 mM) (A) before and (B) after treatment 
with CYP450 reductase (10 g/mL) in the presence of -NADPH (2 mM) at 37 ˚C for 1 















Figure 4. Plausible activation pathways of 13C-IQ-Gd leading to elimination of 
DTPA-Gd unit followed by alkylation of the resulting iminium intermediate. 
 
